When you prescribe Teva’s COPAXONE®, you and your patients can trust in the patient services and support provided by Teva’s Shared Solutions®
Healthcare Professional Services ›
Full range of services to help manage your patients on COPAXONE®
*Applies only to 3-times-a-week COPAXONE® 40 mg. Certain limits and restrictions apply. See Terms and Conditions.
Financial Solutions ›
Helping your patients find financial solutions to start and stay on their COPAXONE® treatment
Support for Starting Therapy ›
Starting your patients on COPAXONE®
Support for Staying Compliant ›
Helping your patients stay committed with COPAXONE®
Injection Training ›
In-home instruction for patients at any stage of therapy
Injections for 3-times-a-week COPAXONE® 40 mg must be at least 48 hours apart.
COPAXONE® is contraindicated in patients with known hypersensitivity to glatiramer acetate or mannitol.
Approximately 16% of patients exposed to COPAXONE® 20 mg per mL compared to 4% of those on placebo, and approximately 2% of
The website you are about to visit does not belong to Teva Neuroscience, Inc. or follow the same terms of service. Some of these websites may also require a third-party account, subscription, or payment to view.
While we carefully choose which websites we link to, we cannot control any changes or actions made by them. As a result, Teva makes no warranties or representations of any kind as to the accuracy, currency, or completeness of the following site, nor any liability on their behalf.